Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 13/20 | 0.63 |
| ▸ | ACP1 | P24666 | 12/20 | 0.63 |
| ▸ | PTPN2 | P17706 | 6/20 | 0.58 |
| ▸ | PTPRF | P10586 | 2/20 | 0.58 |
| ▸ | PTPRB | P23467 | 2/20 | 0.58 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.54 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25191741 | 0.90 | PTPN1 (0.69) | PTPN1ACP1PTPN2PTPRFPTPRB | |
| SCHEMBL25202217 | 0.85 | PTPN1 (0.63) | PTPN1ACP1PTPN2PTPRFPTPRB | |
| SCHEMBL25214975 | 0.84 | PTPN1 (0.65) | PTPN1ACP1PTPN2PTPRFPTPRB | |
| SCHEMBL25216522 | 0.84 | PTPN1 (0.71) | PTPN1ACP1PTPN2PTPRFPTPRB | |
| SCHEMBL25193814 | 0.83 | PTPN1 (0.68) | PTPN1ACP1PTPN2PTPRFPTPRB | |
| SCHEMBL25194385 | 0.83 | PTPN1 (0.65) | PTPN1ACP1PTPN2PTPRFPTPRB | |
| SCHEMBL25285016 | 0.83 | PTPN1 (0.84) | PTPN1ACP1PTPN2PTPRFPTPRB | |
| SCHEMBL25195356 | 0.83 | PTPN1 (0.70) | PTPN1ACP1PTPN2PTPRFPTPRB | |
| SCHEMBL25223704 | 0.83 | PTPN1 (0.64) | PTPN1ACP1PTPN2PTPRFPTPRB | |
| SCHEMBL25199034 | 0.82 | PTPN1 (0.69) | PTPN1ACP1PTPN2PTPRFPTPRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | PTPN1 1308/4885ACP1 2716/4885PTPN2 1928/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | PTPN1 1520/4885ACP1 1174/4885PTPN2 1912/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | PTPN1 1520/4885ACP1 1174/4885PTPN2 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.